WO2005087811A3 - Estrogen receptors and methods of use - Google Patents
Estrogen receptors and methods of use Download PDFInfo
- Publication number
- WO2005087811A3 WO2005087811A3 PCT/US2005/007857 US2005007857W WO2005087811A3 WO 2005087811 A3 WO2005087811 A3 WO 2005087811A3 US 2005007857 W US2005007857 W US 2005007857W WO 2005087811 A3 WO2005087811 A3 WO 2005087811A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- polypeptides
- estrogen receptors
- antibodies
- seq
- Prior art date
Links
- 102000015694 estrogen receptors Human genes 0.000 title 1
- 108010038795 estrogen receptors Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Abstract
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020067020936A KR20070033965A (en) | 2004-03-10 | 2005-03-10 | Estrogen Receptor and How to Use |
ES05725183.7T ES2533002T3 (en) | 2004-03-10 | 2005-03-10 | Estrogen receptors and methods of use |
CN2005800074678A CN1930188B (en) | 2004-03-10 | 2005-03-10 | Estrogen receptors and methods of use |
AU2005222395A AU2005222395B2 (en) | 2004-03-10 | 2005-03-10 | Estrogen receptors and methods of use |
EP05725183.7A EP1730195B1 (en) | 2004-03-10 | 2005-03-10 | Estrogen receptors and methods of use |
US10/591,199 US7745230B2 (en) | 2004-03-10 | 2005-03-10 | Estrogen receptors and methods of use |
CA2559144A CA2559144C (en) | 2004-03-10 | 2005-03-10 | Estrogen receptor alpha splice variant er-.alpha.36 |
JP2007502975A JP5307393B2 (en) | 2004-03-10 | 2005-03-10 | Estrogen receptor and method of use |
HK07109926.3A HK1104563A1 (en) | 2004-03-10 | 2007-09-12 | Estrogen receptors and methods of use |
US12/825,057 US8013127B2 (en) | 2004-03-10 | 2010-06-28 | Antibody that binds to ER-α36 |
US13/177,523 US8263738B2 (en) | 2004-03-10 | 2011-07-06 | Estrogen receptors and methods of use |
US13/568,144 US8551776B2 (en) | 2004-03-10 | 2012-08-07 | Estrogen receptors and methods of use |
US13/568,141 US8512952B2 (en) | 2004-03-10 | 2012-08-07 | Estrogen receptors and methods of use |
US13/568,145 US8617833B2 (en) | 2004-03-10 | 2012-08-07 | Estrogen receptors and methods of use |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55206704P | 2004-03-10 | 2004-03-10 | |
US60/552,067 | 2004-03-10 | ||
US64346905P | 2005-01-13 | 2005-01-13 | |
US60/643,469 | 2005-01-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/591,199 A-371-Of-International US7745230B2 (en) | 2004-03-10 | 2005-03-10 | Estrogen receptors and methods of use |
US12/825,057 Continuation US8013127B2 (en) | 2004-03-10 | 2010-06-28 | Antibody that binds to ER-α36 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005087811A2 WO2005087811A2 (en) | 2005-09-22 |
WO2005087811A3 true WO2005087811A3 (en) | 2006-03-30 |
Family
ID=34976296
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/007857 WO2005087811A2 (en) | 2004-03-10 | 2005-03-10 | Estrogen receptors and methods of use |
Country Status (10)
Country | Link |
---|---|
US (6) | US7745230B2 (en) |
EP (1) | EP1730195B1 (en) |
JP (2) | JP5307393B2 (en) |
KR (1) | KR20070033965A (en) |
CN (2) | CN102504025B (en) |
AU (1) | AU2005222395B2 (en) |
CA (1) | CA2559144C (en) |
ES (1) | ES2533002T3 (en) |
HK (1) | HK1104563A1 (en) |
WO (1) | WO2005087811A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070033965A (en) | 2004-03-10 | 2007-03-27 | 크레이톤 유니버시티 | Estrogen Receptor and How to Use |
JP5265556B2 (en) * | 2006-10-25 | 2013-08-14 | シェノゲン・ファーマ・グループ・リミテッド | Compounds and methods for treating estrogen receptor related diseases |
HU0700534D0 (en) | 2006-11-24 | 2007-10-29 | Mezoegazdasagi Biotechnologiai | Transgenic animal with enhanced immune response and method for the preparation thereof |
US20110311517A1 (en) * | 2009-02-10 | 2011-12-22 | Shenogen Pharma Group, Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
CN102307595A (en) * | 2009-02-10 | 2012-01-04 | 盛诺基医药科技有限公司 | Antibodies and methods for treating estrogen receptor-associated diseases |
US8815779B2 (en) | 2009-09-16 | 2014-08-26 | SwitchGear Genomics, Inc. | Transcription biomarkers of biological responses and methods |
US8841269B2 (en) * | 2010-02-23 | 2014-09-23 | Creighton University | Polynucleotides for use in treating and diagnosing cancers |
EP2627671A1 (en) * | 2010-10-15 | 2013-08-21 | Université Libre de Bruxelles | Estrogen receptor alpha polypeptide sequence, diagnostic and therapeutic applications thereof |
EP3514267B1 (en) * | 2011-09-22 | 2020-11-25 | Expression Pathology, Inc. | Multiplex mrm assay for evaluation of cancer |
JP6265119B2 (en) * | 2012-03-30 | 2018-01-24 | コニカミノルタ株式会社 | Biological substance detection method |
CN105263962B (en) * | 2013-03-19 | 2019-12-31 | 北京盛诺基医药科技股份有限公司 | Antibodies and methods for treating estrogen receptor-related diseases |
EP2976362B1 (en) * | 2013-03-19 | 2019-10-23 | Beijing Shenogen Pharma Group Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
WO2015010596A1 (en) * | 2013-07-22 | 2015-01-29 | 北京盛诺基医药科技有限公司 | Prognosis diagnosis method of breast cancer |
US11610644B2 (en) * | 2014-10-24 | 2023-03-21 | Koninklijke Philips N.V. | Superior bioinformatics process for identifying at risk subject populations |
GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
KR101763580B1 (en) | 2015-09-15 | 2017-08-01 | 숙명여자대학교산학협력단 | Method for screening agent for Estrogen receptor mediated diseases using Human glutathione S-transferase P1-1 |
CN108191976A (en) * | 2017-12-18 | 2018-06-22 | 青岛珅奥基生物工程有限公司 | A kind of anti-36 monoclonal antibodies of ER- α |
CN107987164B (en) * | 2017-12-18 | 2021-02-19 | 青岛珅奥基生物工程有限公司 | Estrogen receptor ER-alpha 36 antigen polypeptide and monoclonal antibody thereof |
CN114874326B (en) * | 2022-06-21 | 2023-01-17 | 图凌(杭州)生物医药有限公司 | Monoclonal antibody for detecting estrogen receptor alpha, and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000823A1 (en) * | 1999-06-29 | 2001-01-04 | European Molecular Biology Laboratory | NOVEL ISOFORMS OF THE HUMAN ESTROGEN RECEPTOR-$g(a) |
WO2001062969A2 (en) * | 2000-02-22 | 2001-08-30 | Pe Corporation (Ny) | Estrogen receptor alpha variants and methods of detection thereof |
WO2002097044A2 (en) * | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4784949A (en) | 1984-04-19 | 1988-11-15 | Cetus Corporation | Universal dominant selectable marker cassette |
DE3583940D1 (en) | 1984-10-02 | 1991-10-02 | Harry M Meade | PRODUCTION OF STREPTAVIDINE-LIKE POLYPEPTIDES. |
US5560922A (en) | 1986-05-30 | 1996-10-01 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5788983A (en) | 1989-04-03 | 1998-08-04 | Rutgers, The State University Of New Jersey | Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes |
US5312752A (en) | 1989-07-31 | 1994-05-17 | Trustees Of Boston University | Specific antibodies against the DNA-binding domain of and immunoassays to determine the presence and functional status of estrogen receptor proteins |
US5053133A (en) | 1990-02-09 | 1991-10-01 | Elias Klein | Affinity separation with activated polyamide microporous membranes |
US5595887A (en) | 1990-07-16 | 1997-01-21 | Bionebraska, Inc. | Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment |
EP0703989B1 (en) * | 1993-06-18 | 1997-11-05 | Oy Biotie Therapies | COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6 |
EP0888543A4 (en) | 1996-03-20 | 2004-04-07 | Scripps Research Inst | Azatide peptidomimetics |
US6306434B1 (en) | 1997-02-12 | 2001-10-23 | Chong Kun Dang Corp. | Pharmaceutical composition comprising cyclosporin solid-state microemulsion |
GB9716790D0 (en) | 1997-08-07 | 1997-10-15 | Creative Peptides Sweden Ab | Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof |
US6365146B1 (en) | 1999-04-23 | 2002-04-02 | Rutgers, The State University Of New Jersey | Polymer encapsulation of hydrophobic materials |
US6416758B1 (en) | 1999-04-28 | 2002-07-09 | Board Of Regents, The University Of Texax System | Antibody conjugate kits for selectively inhibiting VEGF |
DE60130852T2 (en) | 2000-06-12 | 2008-07-17 | Fujirebio Inc. | Immunoassay for measuring the human C-peptide and reagent kit therefor |
US20060287226A9 (en) | 2001-06-15 | 2006-12-21 | Deecher Darlene C | Characterization of a membrane estrogen receptor |
US20060240016A1 (en) * | 2001-12-18 | 2006-10-26 | Luc Aguilar | Activity of THAP-family chemokine-binding domains |
US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
WO2004016653A2 (en) | 2002-08-15 | 2004-02-26 | Leukotech A/S | Bactericidal, anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp) or human neutrophil elastase |
US20030044412A1 (en) | 2002-08-26 | 2003-03-06 | Pietras Richard J. | Membrane estrogen receptor-directed therapy in breast cancer |
KR20070033965A (en) | 2004-03-10 | 2007-03-27 | 크레이톤 유니버시티 | Estrogen Receptor and How to Use |
US20110311517A1 (en) * | 2009-02-10 | 2011-12-22 | Shenogen Pharma Group, Ltd. | Antibodies and methods for treating estrogen receptor-associated diseases |
US8841269B2 (en) * | 2010-02-23 | 2014-09-23 | Creighton University | Polynucleotides for use in treating and diagnosing cancers |
-
2005
- 2005-03-10 KR KR1020067020936A patent/KR20070033965A/en not_active Application Discontinuation
- 2005-03-10 JP JP2007502975A patent/JP5307393B2/en not_active Expired - Fee Related
- 2005-03-10 ES ES05725183.7T patent/ES2533002T3/en active Active
- 2005-03-10 CA CA2559144A patent/CA2559144C/en active Active
- 2005-03-10 CN CN201110351822.0A patent/CN102504025B/en active Active
- 2005-03-10 EP EP05725183.7A patent/EP1730195B1/en active Active
- 2005-03-10 US US10/591,199 patent/US7745230B2/en active Active
- 2005-03-10 CN CN2005800074678A patent/CN1930188B/en active Active
- 2005-03-10 AU AU2005222395A patent/AU2005222395B2/en active Active
- 2005-03-10 WO PCT/US2005/007857 patent/WO2005087811A2/en active Application Filing
-
2007
- 2007-09-12 HK HK07109926.3A patent/HK1104563A1/en unknown
-
2010
- 2010-06-28 US US12/825,057 patent/US8013127B2/en not_active Expired - Fee Related
-
2011
- 2011-07-06 US US13/177,523 patent/US8263738B2/en active Active
-
2012
- 2012-08-07 US US13/568,144 patent/US8551776B2/en active Active
- 2012-08-07 US US13/568,145 patent/US8617833B2/en active Active
- 2012-08-07 US US13/568,141 patent/US8512952B2/en active Active
-
2013
- 2013-03-05 JP JP2013043135A patent/JP5873034B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001000823A1 (en) * | 1999-06-29 | 2001-01-04 | European Molecular Biology Laboratory | NOVEL ISOFORMS OF THE HUMAN ESTROGEN RECEPTOR-$g(a) |
WO2001062969A2 (en) * | 2000-02-22 | 2001-08-30 | Pe Corporation (Ny) | Estrogen receptor alpha variants and methods of detection thereof |
WO2002097044A2 (en) * | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Alternative splice forms of proteins as basis for multiple therapeutic modalities |
Non-Patent Citations (2)
Title |
---|
DATABASE EMBL-SVA [online] 28 August 2003 (2003-08-28), "Homo sapiens mRNA; cDNA DKFZp686N23123 (from clone DKFZp686N23123)", XP002354993, retrieved from EBI accession no. EM_PRO:BX640939 Database accession no. BX640939.1 * |
JAZAERI O ET AL: "EXPRESSION OF ESTROGEN RECEPTOR ALPHA MRNA AND PROTEIN VARIANTS IN HUMAN ENDOMETRIAL CARCINOMA", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 74, no. 1, 1999, pages 38 - 47, XP001011870, ISSN: 0090-8258 * |
Also Published As
Publication number | Publication date |
---|---|
CA2559144A1 (en) | 2005-09-22 |
US20120321634A1 (en) | 2012-12-20 |
US8551776B2 (en) | 2013-10-08 |
CN1930188B (en) | 2012-01-11 |
CN1930188A (en) | 2007-03-14 |
ES2533002T3 (en) | 2015-04-06 |
JP5873034B2 (en) | 2016-03-01 |
US8263738B2 (en) | 2012-09-11 |
EP1730195B1 (en) | 2015-01-14 |
WO2005087811A2 (en) | 2005-09-22 |
AU2005222395A1 (en) | 2005-09-22 |
US20130011847A1 (en) | 2013-01-10 |
US20120016109A1 (en) | 2012-01-19 |
US8617833B2 (en) | 2013-12-31 |
US20100285018A1 (en) | 2010-11-11 |
JP2007528406A (en) | 2007-10-11 |
EP1730195A2 (en) | 2006-12-13 |
US7745230B2 (en) | 2010-06-29 |
AU2005222395B2 (en) | 2012-02-16 |
CA2559144C (en) | 2014-01-21 |
HK1104563A1 (en) | 2008-01-18 |
CN102504025B (en) | 2015-10-21 |
US8512952B2 (en) | 2013-08-20 |
KR20070033965A (en) | 2007-03-27 |
US20070258895A1 (en) | 2007-11-08 |
US20120322149A1 (en) | 2012-12-20 |
JP2013153751A (en) | 2013-08-15 |
CN102504025A (en) | 2012-06-20 |
US8013127B2 (en) | 2011-09-06 |
JP5307393B2 (en) | 2013-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005087811A3 (en) | Estrogen receptors and methods of use | |
MX348154B (en) | IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF. | |
WO2005051998A3 (en) | Antibodies binding to a c-terminal fragment of apolipoprotein e | |
EA200700136A1 (en) | ANTI-CD154-ANTIBODIES | |
WO2001055327A8 (en) | Nucleic acids, proteins, and antibodies | |
WO2007019545A3 (en) | Tissue protective peptides and uses thereof | |
WO2008089053A3 (en) | Gp100-specific t cell receptors and related materials and methods of use | |
WO2003020932A1 (en) | Novel secretory proteins and dna thereof | |
MX2011008759A (en) | Means and methods for manufacturing highly pure neurotoxin. | |
PT1214600E (en) | DETERMINATION OF PROTEINS FROM LIGACAO TO ADRENOMEDULIN | |
WO2007029262A3 (en) | Compositions and methods using same for the detection of viruses | |
WO2000035950A3 (en) | Reagents and methods useful for detecting diseases of the breast | |
WO2003046205A3 (en) | Methods for identifying modulators of apoptosis | |
WO2008142664A3 (en) | Exposed thymidine kinase 1 peptides, ligands and methods employing the same | |
EP1212340A4 (en) | 29 human cancer associated proteins | |
WO2004072223A3 (en) | Identification and characterization of racemases, definition of protein signatures, and a test for detecting d-amino acid and for screening molecules capable of inhibiting the activity of racemase, especially proline racemase | |
WO2005042717A3 (en) | Primate prokineticin and prokineticin receptor polypeptides, related compositions and methods | |
WO2006038101A3 (en) | Novel cancer associated antibodies and antigens and their use in cancer diagnosis | |
CY1111630T1 (en) | CYCLING PRODUCERS | |
WO2009083968A8 (en) | Novel protein | |
MY150639A (en) | T cell adhesion molecule and antibody thereto | |
WO2007014951A3 (en) | Methods for the screening of antibacterial substances | |
WO2004096855A3 (en) | Methods utilising g-protein coupled receptor 54 | |
WO2005077975A3 (en) | Polypeptides comprising the pleckstrin homology domain of ect2 and their binding specificities to phosphatidylinositols | |
WO2003021262A1 (en) | Screening method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005222395 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5102/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580007467.8 Country of ref document: CN Ref document number: 2007502975 Country of ref document: JP Ref document number: 2559144 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005222395 Country of ref document: AU Date of ref document: 20050310 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005222395 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067020936 Country of ref document: KR Ref document number: 2005725183 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005725183 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067020936 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10591199 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10591199 Country of ref document: US |